Rethinking HIV prevention to prepare for oral PrEP implementation for young African women

Journal of the International AIDS Society

Volumn 18, Issue , 2015, Pages

  Celum, Connie L ^a   Delany Moretlwe, Sinead ^b   McConnell, Margaret ^c   Van Rooyen, Heidi ^d   Bekker, Linda Gail ^e   Kurth, Ann ^f   Bukusi, Elizabeth ^g   Desmond, Chris ^d   Morton, Jennifer ^a   Baeten, Jared M ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d HUMAN SCIENCES RESEARCH COUNCIL   (South Africa)

^e UNIVERSITY OF CAPE TOWN   (South Africa)

^f NEW YORK UNIVERSITY   (United States)

^g KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

Author keywords

Africa; HIV; Pre exposure prophylaxis; Prevention; Women

Indexed keywords

BEHAVIORAL ECONOMICS; CONDOM USE; FEMALE; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEDICATION COMPLIANCE; PATIENT COMPLIANCE; PRE-EXPOSURE PROPHYLAXIS; PRIORITY JOURNAL; REVIEW; SEXUALITY; SOCIAL MARKETING; ADOLESCENT; ADULT; AFRICA; HIV INFECTIONS; ORAL DRUG ADMINISTRATION;

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AFRICA; ANTI-HIV AGENTS; FEMALE; HIV INFECTIONS; HUMANS; PRE-EXPOSURE PROPHYLAXIS;

EID: 84938222186     PISSN: None     EISSN: 17582652     Source Type: Journal    
DOI: 10.7448/IAS.18.4.20227     Document Type: Review

References (123)

1. UNAIDS. The Gap Report. Geneva: Joint United Nations Programme on HIV/AIDS (UNAIDS); 2014.
2. Ng'ang'a A, Waruiru W, Ngare C, Ssempijja V, Gachuki T, Njoroge I, et al. The status of HIV testing and counseling in Kenya: Results from a nationally representative population-based survey. J Acquir Immune Defic Syndr. 2014; 66(Suppl 1):S27-36.
3. Lahuerta M, Wu Y, Hoffman S, Elul B, Kulkarni SG, Remien RH, et al. Advanced HIV disease at entry into HIV care and initiation of antiretroviral therapy during 2006-2011: Findings from four sub-saharan African countries. Clin Infect Dis. 2014;58(3):432-41.
4. Wasserheit JN. Epidemiological synergy. Interrelationships between human immunodeficiency virus infection and other sexually transmitted diseases. Sex Transm Dis. 1992;19(2):61-77.
5. Rottingen JA, Cameron DW, Garnett GP. A systematic review of the epidemiologic interactions between classic sexually transmitted diseases and HIV: How much really is known? Sex Transm Dis. 2001;28(10):579-97.
6. Hayes R, Watson-Jones D, Celum C, Van de Wijgert J, Wasserheit J. Treatment of sexually transmitted infections for HIV prevention: End of the road or new beginning? AIDS. 2010;24(Suppl 4):S15-26.
7. Celum CL. Sexually transmitted infections and HIV: Epidemiology and interventions. Top HIV Med. 2010;18(4):138-42.
8. Naranbhai V, Abdool Karim SS, Altfeld M, Samsunder N, Durgiah R, Sibeko S, et al. Innate immune activation enhances HIV acquisition in women, diminishing the effectiveness of tenofovir microbicide gel. J Infect Dis. 2012; 206(7):993-1001.
9. Gray RH, Kiwanuka N, Quinn TC, Sewankambo NK, Serwadda D, Mangen FW, et al. Male circumcision and HIV acquisition and transmission: Cohort studies in Rakai, Uganda. Rakai Project Team. AIDS. 2000;14(15):2371-81.
10. Baeten JM, Donnell D, Kapiga SH, Ronald A, John-Stewart G, Inambao M, et al. Male circumcision and risk of male-to-female HIV-1 transmission: A multinational prospective study in African HIV-1-serodiscordant couples. AIDS. 2010;24(5):737-44.
11. Gray RH, Wawer MJ, Brookmeyer R, Sewankambo NK, Serwadda D, Wabwire-Mangen F, et al. Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda. Lancet. 2001;357(9263):1149-53.
12. Hughes JP, Baeten JM, Lingappa JR, Magaret AS, Wald A, de Bruyn G, et al. Determinants of per-coital-act HIV-1 infectivity among African HIV-1-serodiscordant couples. J Infect Dis. 2012;205(3):358-65.
13. Gray RH, Li X, Kigozi G, Serwadda D, Brahmbhatt H, Wabwire-Mangen F, et al. Increased risk of incident HIV during pregnancy in Rakai, Uganda: A prospective study. Lancet. 2005;366(9492):1182-8.
14. Polis CB, Curtis KM. Use of hormonal contraceptives and HIV acquisition in women: A systematic review of the epidemiological evidence. Lancet Infect Dis. 2013;13(9):797-808.
15. Pettifor AE, Van Der Straten A, Dunbar MS, Shiboski SC, Padian NS. Early age of first sex: A risk factor for HIV infection among women in Zimbabwe. AIDS. 2004;18(10):1435-42.
16. Pettifor A, O'Brien K, Macphail C, Miller WC, Rees H. Early coital debut and associated HIV risk factors among young women and men in South Africa. Int Perspect Sex Reprod Health. 2009;35(2):82-90.
17. Hallett TB, Gregson S, Lewis JJ, Lopman BA, Garnett GP. Behaviour change in generalised HIV epidemics: Impact of reducing cross-generational sex and delaying age at sexual debut. Sex Transm Infect. 2007;83(Suppl 1):i50-4.
18. Halperin DT, Epstein H. Concurrent sexual partnerships help to explain Africa's high HIV prevalence: Implications for prevention. Lancet. 2004;364 (9428):4-6.
19. Mah TL, Halperin DT. Concurrent sexual partnerships and the HIV epidemics in Africa: Evidence to move forward. AIDS Behav. 2010;14(1):11-6.
20. Reddy SP JS, Sewpaul R, Koopman F, Funani NI, Sifunda S, Josie J, et al. Umthente Uhlaba Usamila-The South African Youth Risk Behaviour Survey 2008. Cape Town: South African Medical Research Council; 2010.
21. Jewkes RK, Dunkle K, Nduna M, Shai N. Intimate partner violence, relationship power inequity, and incidence of HIV infection in young women in South Africa: A cohort study. Lancet. 2010;376(9734):41-8.
22. Jewkes RK, Levin JB, Penn-Kekana LA. Gender inequalities, intimate partner violence and HIV preventive practices: Findings of a South African crosssectional study. Soc Sci Med. 2003;56(1):125-34.
23. Fisher JC, Bang H, Kapiga SH. The association between HIV infection and alcohol use: A systematic review and meta-analysis of African studies. Sex Transm Dis. 2007;34(11):856-63.
24. Gupta GR, Parkhurst JO, Ogden JA, Aggleton P, Mahal A. Structural approaches to HIV prevention. Lancet. 2008;372(9640):764-75.
25. Garcia-Moreno C, Jansen HA, Ellsberg M, Heise L, Watts CH. Health WHOM-cSoWs, Domestic violence against women study T. Prevalence of intimate partner violence: Findings from the WHO multi-country study on women's health and domestic violence. Lancet. 2006;368(9543):1260-9.
26. Coates TJ, Richter L, Caceres C. Behavioural strategies to reduce HIV transmission: How to make them work better. Lancet. 2008;372(9639):669-84.
27. Mavedzenge S, Luecke E, Ross D. Effective approaches for programming to reduce adolescent vulnerability to HIV infection, risk, and HIV-related morbidity and mortality. J Acquir Immune Defic Syndr. 2014;66(Suppl 2):S154-69.
28. Cowan FM, Pascoe SJ, Langhaug LF, Mavhu W, Chidiya S, Jaffar S, et al. The Regai Dzive Shiri project: Results of a randomized trial of an HIV prevention intervention for youth. AIDS. 2010;24(16):2541-52.
29. Doyle AM, Ross DA, Maganja K, Baisley K, Masesa C, Andreasen A, et al. Long-term biological and behavioural impact of an adolescent sexual health intervention in Tanzania: Follow-up survey of the community-based MEMA kwa Vijana Trial. PLoS Med. 2010;7(6):e1000287.
30. Pettifor AE, Kleinschmidt I, Levin J, Rees HV, MacPhail C, Madikizela-Hlongwa L, et al. A community-based study to examine the effect of a youth HIV prevention intervention on young people aged 15-24 in South Africa: Results of the baseline survey. Trop Med Int Health. 2005;10(10):971-80.
31. Jewkes R, Nduna M, Levin J, Jama N, Dunkle K, Puren A, et al. Impact of stepping stones on incidence of HIV and HSV-2 and sexual behaviour in rural South Africa: Cluster randomised controlled trial. BMJ. 2008;337:a506.
32. NIMH Collaborative HIV/STD Prevention Trial Group. Results of the NIMH collaborative HIV/sexually transmitted disease prevention trial of a community popular opinion leader intervention. J Acquir Immune Defic Syndr. 2010; 54(2):204-14.
33. Wingood GM, Scd, DiClemente RJ. Application of the theory of gender and power to examine HIV-related exposures, risk factors, and effective interventions for women. Health Educ Behav. 2000;27(5):539-65.
34. Wight D, Plummer M, Ross D. The need to promote behaviour change at the cultural level: One factor explaining the limited impact of the MEMA kwa Vijana adolescent sexual health intervention in rural Tanzania. A process evaluation. BMC Public Health. 2012;12:788.
35. Underwood C, Skinner J, Osman N, Schwandt H. Structural determinants of adolescent girls' vulnerability to HIV: Views from community members in Botswana, Malawi, and Mozambique. Soc Sci Med. 2011;73(2):343-50.
36. Hawkins K, Price N, Mussa F. Milking the cow: Young women's construction of identity and risk in age-disparate transactional sexual relationships in Maputo, Mozambique. Glob Public Health. 2009;4(2):169-82.
37. Silberschmidt M, Rasch V. Adolescent girls, illegal abortions and ''sugardaddies'' in Dar es Salaam: Vulnerable victims and active social agents. Soc Sci Med. 2001;52(12):1815-26.
38. Wamoyi J, Wight D, Plummer M, Mshana GH, Ross D. Transactional sex amongst young people in rural northern Tanzania: An ethnography of young women's motivations and negotiation. Reprod Health. 2010;7:2.
39. Hunter M. The materiality of everyday sex: Thinking beyond 'prostitution'. Afr Stud. 2002;61(1):99-120.
40. Wamoyi J, Fenwick A, Urassa M, Zaba B, Stones W. ''Women's bodies are shops'': Beliefs about transactional sex and implications for understanding gender power and HIV prevention in Tanzania. Arch Sex Behav. 2011;40(1): 5-15.
41. Pronyk PM, Kim JC, Abramsky T, Phetla G, Hargreaves JR, Morison LA, et al. A combined microfinance and training intervention can reduce HIV risk behaviour in young female participants. AIDS. 2008;22(13):1659-65.
42. Wagman JA, Gray RH, Campbell JC, Thoma M, Ndyanabo A, Ssekasanvu J, et al. Effectiveness of an integrated intimate partner violence and HIV prevention intervention in Rakai, Uganda: Analysis of an intervention in an existing cluster randomised cohort. Lancet Glob Health. 2015;3(1):23-33.
43. U.S. President's Emergency Plan for AIDS Relief (PEPFAR). The U.S. President's Emergency Plan for AIDS Relief, The Bill & Melinda Gates Foundation, and The Nike Foundation Partner on $210 million initiative to reduce new HIV infections in adolescent girls and young women. [cited 2014 Apr 16]. Available from: Http://www.pepfar.gov/press/releases/2014/234531.htm
44. Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587-99.
45. Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367(5):399-410.
46. Choopanya K, Martin M, Suntharasamai P, Sangkum U, Mock PA, Leethochawalit M, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): A randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2013;381(9883):2083-90.
47. Thigpen MC, Kebaabetswe PM, Paxton LA, Smith DK, Rose CE, Segolodi TM, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012;367(5):423-34.
48. Baeten JM, Haberer JE, Liu AY, Sista N. Preexposure prophylaxis for HIV prevention: Where have we been and where are we going? J Acquir Immune Defic Syndr. 2013;63(Suppl 2):S122-9.
49. Murnane PM, Celum C, Mugo N, Campbell JD, Donnell D, Bukusi E, et al. Efficacy of preexposure prophylaxis for HIV-1 prevention among high-risk heterosexuals: Subgroup analyses from a randomized trial. AIDS. 2013;27(13): 2155-60.
50. Donnell D, Baeten JM, Bumpus NN, Brantley J, Bangsberg DR, Haberer JE, et al. HIV protective efficacy and correlates of tenofovir blood concentrations in a clinical trial of PrEP for HIV prevention. J Acquir Immune Defic Syndr. 2014; 66:340-8.
51. Van Damme L, Corneli A, Ahmed K, Agot K, Lombaard J, Kapiga S, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2012;367(5):411-22.
52. Marrazzo JM, Ramjee G, Richardson BA, Gomez K, Mgodi N, Nair G, et al. Tenofovir-based preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2015;372(6):509-18.
53. Patterson KB, Prince HA, Kraft E, Jenkins AJ, Shaheen NJ, Rooney JF, et al. Penetration of tenofovir and emtricitabine in mucosal tissues: Implications for prevention of HIV-1 transmission. Sci Transl Med. 2011;3(112):112re4.
54. Louissaint NA, Cao YJ, Skipper PL, Liberman RG, Tannenbaum SR, Nimmagadda S, et al. Single dose pharmacokinetics of oral tenofovir in plasma, peripheral blood mononuclear cells, colonic tissue, and vaginal tissue. AIDS Res Hum Retroviruses. 2013;29(11):1443-50.
55. Hendrix CW. Exploring concentration response in HIV pre-exposure prophylaxis to optimize clinical care and trial design. Cell. 2013;155(3):515-8.
56. Van Der Straten A, Stadler J, Montgomery E, Hartmann M, Magazi B, Mathebula F, et al. Women's experiences with oral and vaginal pre-exposure prophylaxis: The VOICE-C qualitative study in Johannesburg, South Africa. PLoS One. 2014;9(2):e89118.
57. Van Der Straten A, Stadler J, Luecke E, Laborde N, Hartmann M, Montgomery ET. Perspectives on use of oral and vaginal antiretrovirals for HIV prevention: The VOICE-C qualitative study in Johannesburg, South Africa. J Int AIDS Soc. 2014;17(3 Suppl 2):19146, doi: Http://dx.doi.org/10.7448/IAS.17.3.19146
58. Corneli A, Wang M, Agot K, Ahmed K, Lombaard J, Van Damme L, et al. Perception of HIV risk and adherence to a daily, investigational pill for HIV prevention in FEM-PrEP. J Acquir Immune Defic Syndr. 2014;67(5):555-63.
59. Corneli AL, McKenna K, Perry B, Ahmed K, Agot K, Malamatsho F, et al. The science of being a study participant: FEM-PrEP participants' explanations for overreporting adherence to the study pills and for the whereabouts of unused pills. J Acquir Immune Defic Syndr. 2015;68(5):578-84.
60. Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, Mansoor LE, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010; 329(5996):1168-74.
61. Rees H, Delaney-Moretlwe S, Baron D, Lombard C, Gray G, Myer L, et al. Facts 001 phase iii trial of pericoital tenofovir 1% gel for HIV prevention in women. Conference on Retroviruses and Opportunistic Infections (CROI); 2015 Feb 23-26; Seattle, WA, USA. Abstract 26LB.
62. McCormack S, Dunn D. Pragmatic open-label randomised trial of preexposure prophylaxis: The PROUD study. Conference on Retroviruses and Opportunistic Infections (CROI); 2015 Feb 23-26, Seattle, WA, USA. Abstract LB22.
63. Baeten J, Heffron R, Kidoguchi L, Mugo N, Bukusi E, Katabira E, et al. Near elimination of HIV transmission in a demonstration project of PrEP and ART. Conference on Retroviruses and Opportunistic Infections (CROI); 2015 Feb 23-26; Seattle, WA, USA. Abstract 24.
64. Bekker L-G, Grant R, Hughes J, Roux S, Amico R, Hendrix C, et al., editors. HPTN 067/ADAPT Cape Town: A comparison of daily and nondaily PrEP dosing in African women. Conference on Retroviruses and Opportunistic Infections (CROI); 2015 Feb 23-26; Seattle, WA, USA. Abstract 978LB.
65. Laibson D. Golden eggs and hyperbolic discounting. Q J Econ. 1997; 112(2):443-77.
66. O'Donoghue T, Rabin M. Doing it now or later. Am Econ Rev. 1999; 89(1):103-24.
67. Linnemayr S. HIV prevention through the lens of behavioral economics. J Acquir Immune Defic Syndr. 2015;68(4):61-3.
68. Kahneman D, Tversky A. Prospect theory analysis of decision under risk. Econometrica. 1979;47(2):263-91.
69. Fox CR, Tversky A. Ambiguity aversion and comparative ignorance. Q J Econ. 1995;110(3):585-603.
70. Bryan G. Ambiguity Aversion Decreases Demand for Partial Insurance: Evidence from African Farmers. London School of Economics and Political Science. 2013. Available from: Https://dl.dropboxusercontent.com/u/7911910/AmbiguityAndInsurance.pdf. Working Paper.
71. Johnson SB, Blum RW, Giedd JN. Adolescent maturity and the brain: The promise and pitfalls of neuroscience research in adolescent health policy. J Adolesc Health. 2009;45(3):216-21.
72. Giedd JN, Blumenthal J, Jeffries NO, Castellanos FX, Liu H, Zijdenbos A, et al. Brain development during childhood and adolescence: A longitudinal MRI study. Nat Neurosci. 1999;2(10):861-3.
73. Baicker K, Mullainathan S, Schwartzstein J. Behavioral Hazard in Health Insurance. National Bureau of Economic Research. 2012. Available from: Http://www.nber.org/papers/w18468.pdf. Working Paper 18468.
74. Mani A, Mullainathan S, Shafir E, Zhao J. Poverty impedes cognitive function. Science. 2013;341(6149):976-80.
75. Shah AK, Mullainathan S, Shafir E. Some consequences of having too little. Science. 2012;338(6107):682-5.
76. Weinstein ND. Optimistic biases about personal risks. Science. 1989; 246(4935):1232-3.
77. Volpp KG, Troxel AB, Pauly MV, Glick HA, Puig A, Asch DA, et al. A randomized, controlled trial of financial incentives for smoking cessation. N Engl J Med. 2009;360(7):699-709.
78. Volpp KG, John LK, Troxel AB, Norton L, Fassbender J, Loewenstein G. Financial incentive-based approaches for weight loss: A randomized trial. JAMA. 2008;300(22):2631-7.
79. Royer H, Stehr M, Sydnor J. Incentives, commitments and habit formation in exercise: Evidence from a field experiment with workers at a Fortune 500 company. National Bureau of Economic Research. 2013. Available from: Http://www.nber.org/papers/w18580.pdf. Working paper 18580.
80. Long JA, Jahnle EC, Richardson DM, Loewenstein G, Volpp KG. Peer mentoring and financial incentives to improve glucose control in African American veterans: A randomized trial. Ann Intern Med. 2012;156(6): 416-24.
81. Heise L, Lutz B, Ranganathan M, Watts C. Cash transfers for HIV prevention: Considering their potential. J Int AIDS Soc. 2013;16(1):18615, doi: Http://dx.doi.org/10.7448/IAS.16.1.18615
82. Baird SJ, Garfein RS, McIntosh CT, Ozler B. Effect of a cash transfer programme for schooling on prevalence of HIV and herpes simplex type 2 in Malawi: A cluster randomised trial. Lancet. 2012;379(9823):1320-9.
83. Pettifor A, MacPhail C, Nguyen N, Rosenberg M. Can money prevent the spread of HIV? A review of cash payments for HIV prevention. AIDS Behav. 2012;16(7):1729-38.
84. Handa S, Halpern CT, Pettifor A, Thirumurthy H. The Government of Kenya's cash transfer program reduces the risk of sexual debut among young people age 15-25. PLoS One. 2014;9(1):e85473.
85. Cluver L, Boyes M, Orkin M, Pantelic M, Molwena T, Sherr L. Child-focused state cash transfers and adolescent risk of HIV infection in South Africa: A propensity-score-matched case-control study. Lancet Glob Health. 2013;1(6): 362-70.
86. Kohler HP, Thornton R. Conditional cash transfers and HIV/AIDS prevention: Unconditionally promising? World Bank Econ Rev. 2012;26(2):165-90.
87. de Walque D, Dow WH, Nathan R, Abdul R, Abilahi F, Gong E, et al. Incentivising safe sex: A randomised trial of conditional cash transfers for HIV and sexually transmitted infection prevention in rural Tanzania. BMJ Open. 2012;2:e000747.
88. De Walque D, Bjorkman-Nyqvist M, Corno L, Svensson J. Evaluating the impact of short term financial incentives on HIV and STI incidence among youth in Lesotho: A randomized trial. 7th IAS Conference on HIV Pathogenesis, Treatment and Prevention; 2013 June 30-July 3; Kuala Lumpur, Malaysia. Abstract TUPDC010.
89. Promberger M, Marteau TM. When do financial incentives reduce intrinsic motivation? comparing behaviors studied in psychological and economic literatures. Health Psychol. 2013;32(9):950-7.
90. Mugo N. No silver bullet: HIV & AIDS challenges and solutions. XIX International AIDS Conference; 2012 Jul 24; Washington, DC, USA. Oral presentation.
91. Roalf DR, Gur RE, Ruparel K, Calkins ME, Satterthwaite TD, Bilker WB, et al. Within-individual variability in neurocognitive performance: Age-and sexrelated differences in children and youths from ages 8 to 21. Neuropsychology. 2014;28(4):506-18.
92. Rapoff M. Adherence to pediatric medical regimens. New York, NY: Kluwer Academic/Plenum; 1999.
93. Tebbi CK. Treatment compliance in childhood and adolescence. Cancer. 1993;71(10 Suppl):3441-9.
94. Pidgeon V. Compliance with chronic illness regimens: School-aged children and adolescents. J Pediatr Nurs. 1989;4(1):36-47.
95. Litt IF, Cuskey WR. Compliance with medical regimens during adolescence. Pediatr Clin North Am. 1980;27(1):3-15.
96. Nakimuli-Mpungu E, Bass JK, Alexandre P, Mills EJ, Musisi S, Ram M, et al. Depression, alcohol use and adherence to antiretroviral therapy in sub-Saharan Africa: A systematic review. AIDS Behav. 2012;16(8):2101-18.
97. Adewuya AO, Afolabi MO, Ola BA, Ogundele OA, Ajibare AO, Oladipo BF, et al. The effect of psychological distress on medication adherence in persons with HIV infection in Nigeria. Psychosomatics. 2010;51(1):68-73.
98. Etienne M, Hossain M, Redfield R, Stafford K, Amoroso A. Indicators of adherence to antiretroviral therapy treatment among HIV/AIDS patients in 5 African countries. J Int Assoc Physicians AIDS Care (Chic). 2010;9(2):98-103.
99. Murray LK, Semrau K, McCurley E, Thea DM, Scott N, Mwiya M, et al. Barriers to acceptance and adherence of antiretroviral therapy in urban Zambian women: A qualitative study. AIDS Care. 2009;21(1):78-86.
100. Berenson AB, Rahman M. A randomized controlled study of two educational interventions on adherence with oral contraceptives and condoms. Contraception. 2012;86(6):716-24.
101. Rosenberg MJ, Waugh MS. Oral contraceptive discontinuation: A prospective evaluation of frequency and reasons. Am J Obstet Gynecol. 1998;179(3 Pt1):577-82.
102. Molloy GJ, Graham H, McGuinness H. Adherence to the oral contraceptive pill: A cross-sectional survey of modifiable behavioural determinants. BMC Public Health. 2012;12:838.
103. Safren SA, Otto MW,Worth JL, Salomon E, Johnson W, Mayer K, et al. Two strategies to increase adherence to HIV antiretroviral medication: Life-steps and medication monitoring. Behavior Res Ther. 2001;39(10):1151-62.
104. Safren SA, O'Cleirigh C, Tan JY, Raminani SR, Reilly LC, Otto MW, et al. A randomized controlled trial of cognitive behavioral therapy for adherence and depression (CBT-AD) in HIV-infected individuals. Health Psychol. 2009; 28(1):1-10.
105. Simoni JM, Huh D, Frick PA, Pearson CR, Andrasik MP, Dunbar PJ, et al. Peer support and pager messaging to promote antiretroviral modifying therapy in Seattle: A randomized controlled trial. J Acquir Immune Defic Syndr. 2009;52(4):465-73.
106. Wethington HR, Hahn RA, Fuqua-Whitley DS, Sipe TA, Crosby AE, Johnson RL, et al. The effectiveness of interventions to reduce psychological harm from traumatic events among children and adolescents: A systematic review. Am J Prev Med. 2008;35(3):287-313.
107. Cohen JA, Mannarino AP, Murray LK. Trauma-focused CBT for youth who experience ongoing traumas. Child Abuse Negl. 2011;35(8):637-46.
108. Kennard B, Brown L, Hawkins L, Risi A, Radcliffe J, Emslie G, et al. Development and implementation of health and wellness CBT for individuals with depression and HIV. Cogn Behav Pract. 2014;21(2):237-46.
109. Papas RK, Sidle JE, Gakinya BN, Baliddawa JB, Martino S, Mwaniki MM, et al. Treatment outcomes of a stage 1 cognitive-behavioral trial to reduce alcohol use among human immunodeficiency virus-infected out-patients in western Kenya. Addiction. 2011;106(12):2156-66.
110. Bolton P, Bass J, Betancourt T, Speelman L, Onyango G, Clougherty KF, et al. Interventions for depression symptoms among adolescent survivors of war and displacement in northern Uganda: A randomized controlled trial. JAMA. 2007;298(5):519-27.
111. Bolton P, Bass J, Neugebauer R, Verdeli H, Clougherty KF, Wickramaratne P, et al. Group interpersonal psychotherapy for depression in rural Uganda: A randomized controlled trial. JAMA. 2003;289(23):3117-24.
112. Rahman A, Malik A, Sikander S, Roberts C, Creed F. Cognitive behaviour therapy-based intervention by community health workers for mothers with depression and their infants in rural Pakistan: A cluster-randomised controlled trial. Lancet. 2008;372(9642):902-9.
113. Psaros C, Haberer JE, Katabira E, Ronald A, Tumwesigye E, Campbell JD, et al. An intervention to support HIV preexposure prophylaxis adherence in HIV-serodiscordant couples in Uganda. J Acquir Immune Defic Syndr. 2014;66(5):522-9.
114. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353(5):487-97.
115. Finitsis DJ, Pellowski JA, Johnson BT. Text message intervention designs to promote adherence to antiretroviral therapy (ART): A meta-analysis of randomized controlled trials. PLoS One. 2014;9(2):88166.
116. Castano PM, Bynum JY, Andres R, Lara M,Westhoff C. Effect of daily text messages on oral contraceptive continuation: A randomized controlled trial. Obstet Gynecol. 2012;119(1):14-20.
117. Morgan M, Fischhoff B, Bostom A, Atman C. Risk communication: The mental models approach. New York, NY: Cambridge University Press; 2001.
118. O'Keefe DJ, Jensen JD. The relative persuasiveness of gain-framed and loss-framed messages for encouraging disease prevention behaviors: A meta-analytic review. J Health Commun. 2007;12(7):623-44.
119. Ariely D, Loewenstein G. The heat of the moment: The effect of sexual arousal on sexual decision making. J Behav Decis Making. 2006;19:87-98.
120. Datta S, Burns J, Maughan-Brown B, Darling M, Eyal K. Risking it all for love? Resetting beliefs about HIV risk among low-income South African teens. J Econ Behav Organ. [Epub 2015 Mar 3].
121. Balkus JE, Zhang JY, Nair G, Palanee T, Ramjee G, Nakabiito C, et al. Development of a risk scoring tool to predict HIV-1 acquisition in African women. AIDS Res Hum Retroviruses. 2014;30:A214.
122. Sikkema KJ, Neufeld SA, Hansen NB, Mohlahlane R, Van Rensburg MJ, Watt MH, et al. Integrating HIV prevention into services for abused women in South Africa. AIDS Behav. 2010;14(2):431-9.
123. Myers JE, Sepkowitz KA. A pill for HIV prevention: Deja vu all over again? Clin Infect Dis. 2013;56(11):1604-12.